S7067

SB 202190

≥98% (HPLC), powder, p38 MAP kinase inhibitor

• Synonim(y): 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole
• Wzór empiryczny (zapis Hilla): C₂₀H₁₄FN₃O
• Numer CAS: 152121-30-7
• Masa cząsteczkowa: 331.34
• Numer MDL: MFCD00941964
• Kod UNSPSC: 12352200
• Identyfikator substancji w PubChem: 24278272
• NACRES: NA.77

Właściwości

• Nazwa produktu: SB 202190, ≥98% (HPLC)
• Poziom jakości: 100
• Próba: ≥98% (HPLC)
• Formularz: powder
• kolor: faintly yellow, to beige
• rozpuszczalność: DMSO: 10 mg/mL, clear
• inicjator: GlaxoSmithKline
• temp. przechowywania: 2-8°C
• ciąg SMILES: Oc1ccc(cc1)-c2nc(-c3ccc(F)cc3)c([nH]2)-c4ccncc4
• InChI: 1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,25H,(H,23,24)
• Klucz InChI: QHKYPYXTTXKZST-UHFFFAOYSA-N
• informacje o genach: human ... MAPK14(1432)

Opis

Opis ogólny

SB202190 aids in enhancing the self-renewal ability of neural stem cells fromNPC1-deficient mice.[1]

Zastosowanie

SB 202190 has been used:

• to investigate the role of p38mitogen-activated protein kinase (MAPK) signaling in establishment of reovirus infection[2]
• as a p38α inhibitor in in vivo studies to study its impact on the development or progression of adenocarcinoma in the colon mucosa tissues of APC ^Min/+ mice.[3]
• as a component of basic BC medium to culture basal progenitor cells.[4]
• as a component of normal endometrium and endometrial tumor media for organoid culture.[5]

SB 202190 was used to inhibit p38 activation in MCF7 cells⁵, mouse macrophages⁶ and HepG2 cells.⁷

Działania biochem./fizjol.

SB 202190 is a highly selective, potent and cell permeable inhibitor of p38 MAP kinase. SB 202190 binds within the ATP pocket of the active kinase (K_d = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38α and β isoforms.

Cechy i korzyści

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informacje prawne

Sold for research purposes under agreement from Glaxo­Smith­Kline

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 11 - Combustible Solids
• Klasa zagrożenia wodnego (WGK): WGK 3
• Środki ochrony indywidualnej: dust mask type N95 (US), Eyeshields, Gloves